Experimental HBV Drugs
Experimental HBV Drugs
AASLD 2016: GS-4774 Therapeutic Vaccine Shows Little Efficacy in People with Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Wednesday, 30 November 2016 00:00
- Written by Liz Highleyman
An experimental immune-based therapy for chronic hepatitis B combined with tenofovir was safe and well-tolerated, but did not lead to greater reductions in hepatitis B surface antigen (HBsAg) than the antiviral alone, according to a study reported at the AASLD Liver Meeting this month in Boston.
AASLD 2016: Nucleic Acid Polymers Reduce HBsAg Levels and Improve Control of Hepatitis B Virus
- Details
- Category: Experimental HBV Drugs
- Published on Tuesday, 22 November 2016 00:00
- Written by Liz Highleyman
The nucleic acid polymers REP 2139 and REP 2165 led to hepatitis B surface antigen (HBsAg) reduction or clearance when combined with tenofovir and pegylated interferon, according to early results from a small study presented as a late-breaker at the AASLD Liver Meeting this month in Boston. This combination may potentially enable functional control of hepatitis B if confirmed in larger studies.
EASL 2016: Tenofovir Alafenamide Works Well Against Hepatitis B with Less Effect on Bones and Kidneys
- Details
- Category: Experimental HBV Drugs
- Published on Sunday, 17 April 2016 00:00
- Written by Liz Highleyman
The new tenofovir alafenamide (TAF) pro-drug is as potent against hepatitis B virus (HBV) as the current tenofovir disoproxil fumarate (TDF) formulation, but with less detrimental effects on bone and kidney biomarkers, according to a pair of studies presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.
EASL 2016: Core Inhibitor NVR 3-778 Plus Pegylated Interferon Inhibits Hepatitis B Activity
- Details
- Category: Experimental HBV Drugs
- Published on Tuesday, 26 April 2016 00:00
- Written by Liz Highleyman
NVR 3-778, an experimental drug that interferes with hepatitis B virus (HBV) capsid assembly, led to reductions in HBV DNA, HBV RNA, and hepatitis B "e" antigen (HBeAg), showing greater activity when combined with pegylated interferon, researchers reported at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this month in Barcelona.
AASLD 2015: Hepatitis B Core Inhibitor NVR 3-778 Inhibits Viral Replication
- Details
- Category: Experimental HBV Drugs
- Published on Thursday, 21 January 2016 00:00
- Written by Liz Highleyman
Novira Therapeutics' NVR 3-778, a novel drug that interferes with the hepatitis B virus (HBV) core protein, blocked replication of various types of HBV in a laboratory study and reduced HBV viral load with no apparent safety issues in an early human trial, researchers reported at the AASLD Liver Meeting in November.
More Articles...
- AASLD 2015: REP 2139 Shows Promise for People with Hepatitis B and Hepatitis Delta Coinfection
- EASL 2015: Nucleic Acid Polymer REP 2139-Ca Shows Promise Against Hepatitis B and Delta Viruses
- AASLD 2013: Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity
- AASLD 2012: Adding Pegylated Interferon to Entecavir Improves HBV Treatment Response
Web Design and Development by